Plasmodium vivax transmission-blocking vaccines: Progress, challenges and innovation
Plasmodium vivax transmission-blocking vaccines: Progress, challenges and innovation
复制标题
间日疟原虫传播阻断疫苗：进展、挑战和创新
DOI：
10.1016/j.parint.2021.102525
复制
发表时间：
2022
影响因子：
1.9
通讯作者：
Tsuboi Takafumi
中科院分区：
文献类型：
--
作者：
Tachibana Mayumi;Takashima Eizo;Morita Masayuki;Sattabongkot Jetsumon;Ishino Tomoko;Culleton Richard;Torii Motomi;Tsuboi Takafumi
在过去二十年中，现有的控制措施大大降低了疟疾发病率和死亡率，尽管这种降低目前正在停滞。为研制疟疾疫苗作出了重大努力。近年来，针对恶性疟原虫的疟疾疫苗研究取得了广泛进展。迄今为止，只有RTS，S/AS 01疫苗在3期临床试验中进行了测试，目前正在实施中，尽管效果不佳。因此，研制阻断疟疾传播的疫苗对消灭疟疾至关重要。只有有限数量的TBV已经达到临床前或临床开发，有几个主要挑战阻碍了它们的开发，包括人体免疫原性低。防止基于性别的暴力的发展努力间日疟是疟疾发病的第二大原因，远远落后于P。恶性疟原虫。本文综述了P. vivaxTBV的研究和讨论如何加快其发展。
Existing control measures have significantly reduced malaria morbidity and mortality in the last two decades, although these reductions are now stalling. Significant efforts have been undertaken to develop malaria vaccines. Recently, extensive progress in malaria vaccine development has been made forPlasmodium falciparum. To date, only the RTS,S/AS01 vaccine has been tested in Phase 3 clinical trials and is now under implementation, despite modest efficacy. Therefore, the development of a malaria transmission-blocking vaccine (TBV) will be essential for malaria elimination. Only a limited number of TBVs have reached pre-clinical or clinical development with several major challenges impeding their development, including low immunogenicity in humans. TBV development efforts againstP. vivax, the second major cause of malaria morbidity, lag far behind those forP. falciparum. In this review we summarize the latest progress, challenges and innovations inP. vivaxTBV research and discuss how to accelerate its development.